Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$275.8MCash on Hand
71.3mo Cash Runway
Follow SGMT by emailGet an email when SGMT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SGMT, unsubscribe in one click. Privacy
📣 What SGMT Says Is Next
the end of 2026 · TVB-3567: “Plan to initiate TVB-3567 Phase 2 before the end of 2026 Acne”
Company press release, Nov 12, 2026 · SEC filing
1Q 2027 · Denifanstat: “Plan to consult with the FDA regarding a denifanstat-resmetirom combination Phase 2 study design in 1Q 2027, after which we anticipate that the program will be Phase 2 ready”
Company press release, Nov 12, 2026 · SEC filing
the end of 2026 · “Plan to initiate Phase 2 clinical trial before the end of 2026”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 results: R&D expense of $16.3M and net loss of $19.1M for the quarter. Pro forma cash of $355.8M after October offering of $115.0M gross proceeds, expected to fund operations through mid-2029. U.S. AURORA Phase 3 denifanstat topline data expected 2H 2027. Form 8-K · SEC filing · Press release
Oct 22, 2026 ·
Sagimet furnished an updated investor presentation dated October 22, 2026 (Exhibit 99.1) for use in investor meetings. The deck reports that the AURORA Phase 3 acne trial dosed its first patient in October 2026, with topline results expected in 2H 2027, and $257.6M cash as of 6/30/2026. Form 8-K · SEC filing · Press release
Oct 1, 2026 ·
Financing Sagimet plans to sell 8,750,010 Series A common shares, with pre-funded warrants for 2,750,010 shares offered in lieu of shares for some investors. The offering price is $10.00 per share, with proceeds of $108,099,913 before expenses. Form 424B5 · SEC filing
Oct 1, 2026 ·
Financing Sagimet agreed to sell 8,750,010 Series A common shares at $10.00 each and pre-funded warrants for up to 2,750,010 shares, with expected net proceeds of $107.5 million. The offering is expected to close October 1, 2026. Form 8-K · SEC filing
Sep 30, 2026 ·
Financing Sagimet suspended and terminated its at-the-market stock sales program with Leerink Partners effective September 30, 2026. The company had not sold any shares under the Sales Agreement as of the supplement date. Form 424B3 · SEC filing
Sep 30, 2026 ·
Clinical trial Announced positive 52-week results from the Phase 3 ASC40-304 open-label extension trial of denifanstat in moderate to severe acne, run by partner Ascletis in China. Also terminated the ATM prospectus supplement for Series A common stock with Leerink Partners. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Regulatory The FDA cleared the Investigational New Drug application and issued a "Study May Proceed" letter for the Phase 3 trial of denifanstat in moderate to severe acne. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2027 · Phase 1 · Recruiting · Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne Registry primary completion date, not a results date
Aug 2027 · Phase 3 · Recruiting · Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not SGMT's own candidates): Enzalutamide, Resmetirom.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
SGMT holds $275.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $11.6M/quarter from operations,
an estimated runway of 71.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:29 · Moderate
Cash runway 71 months
ATM program on file since Aug 2025 +15
Shelf registration (S-3, Aug 2024) +10
Share count +44% in a year +14
Raised after last reported balance sheet (Oct 2026) -10
Share count 30,674,855 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SGMT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SGMT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.